Chemistry:Temelimab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Legal status | |
| Legal status |
|
Temelimab (also known as GNbAC1[1]) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.[2][3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions.[1] As of 2023, it is also being studied for cognitive impairment in long COVID.[4]
References
- ↑ 1.0 1.1 "Promising role of temelimab in multiple sclerosis treatment". Multiple Sclerosis and Related Disorders 61: 103743. May 2022. doi:10.1016/j.msard.2022.103743. PMID 35344907.
- ↑ "Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?". Multiple Sclerosis and Related Disorders 64: 103938. August 2022. doi:10.1016/j.msard.2022.103938. PMID 35717898.
- ↑ "Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review". Drug Safety 43 (12): 1287–1296. December 2020. doi:10.1007/s40264-020-00988-3. PMID 32794123.
- ↑ "Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative". Frontiers in Immunology 14: 1129459. 2023-03-09. doi:10.3389/fimmu.2023.1129459. PMID 36969241.
 |  |
